{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:51:47Z","timestamp":1761594707170,"version":"build-2065373602"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Several therapies, including sphingosine 1-phosphate receptor modulators, have been approved for ulcerative colitis (UC). Safety findings should be complemented with real-world data (RWD) as rare events may be underestimated in clinical trials due to populations not fully reflecting real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used RWD to investigate safety outcomes in 4 cohorts: (1) those receiving any UC treatment (UC overall), (2) those receiving advanced therapies (UC advanced therapy), (3) those meeting the selection criteria of the etrasimod ELEVATE UC clinical program (UC trial-similar), (4) individuals without UC (Non-UC). Data were extracted (1\/2016\u201312\/2022) from the Optum\u00ae de-identified Electronic Health Record data set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 32\u2005170 (UC overall), 3332 (UC advanced therapy), 1435 (UC trial-similar), and 160\u2005795 (Non-UC) individuals were included. In the UC overall cohort, &amp;lt;11% of patients used advanced therapy. The UC overall cohort had significantly higher incidence rates (IRs) across most safety outcomes compared with the Non-UC cohort (highest: malignancy [excluding non-melanoma skin cancer] at 31.1 compared with 14.1 IRs per 1000 patient-years, respectively), regardless of age or oral corticosteroid use. Incidence rates of safety outcomes for the UC advanced therapy and UC trial-similar (also requiring prior advanced therapy use) cohorts were generally similar or lower than the UC overall cohort. The UC trial-similar and UC advanced therapy cohorts had generally comparable safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings assist in understanding the background risks of safety events in patients with UC and suggest that the incidence of select safety outcomes is comparable between the ELEVATE UC trials and RWD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf067","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:13:35Z","timestamp":1742404415000},"page":"2757-2766","source":"Crossref","is-referenced-by-count":0,"title":["Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States"],"prefix":"10.1093","volume":"31","author":[{"given":"Miguel D","family":"Regueiro","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Bewtra","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Branquinho","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoibhinn","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Sandwich ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4626","authenticated-orcid":false,"given":"Milena A","family":"Gianfrancesco","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"10080","key":"2025102715480129000_CIT0001","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"2025102715480129000_CIT0002","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"43","key":"2025102715480129000_CIT0003","doi-asserted-by":"publisher","first-page":"e35689","DOI":"10.1097\/MD.0000000000035689","article-title":"Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: systematic review and network meta-analysis","volume":"102","author":"Gao","year":"2023","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"2025102715480129000_CIT0004","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"1","key":"2025102715480129000_CIT0005","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025102715480129000_CIT0006","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7861\/clinmedicine.17-5-429","article-title":"Ulcerative colitis: management in adults, children and young people - concise guidance","volume":"17","author":"Tun","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"2025102715480129000_CIT0007","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2025102715480129000_CIT0008","doi-asserted-by":"publisher","first-page":"e0227914","DOI":"10.1371\/journal.pone.0227914","article-title":"Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"15","author":"Armuzzi","year":"2020","journal-title":"PLoS One."},{"key":"2025102715480129000_CIT0009","doi-asserted-by":"publisher","first-page":"102173","DOI":"10.1016\/j.pmedr.2023.102173","article-title":"Inflammatory bowel disease prevalence: surveillance data from the U.S. National Health and Nutrition Examination Survey","volume":"33","author":"Weisman","year":"2023","journal-title":"Prev Med Rep"},{"issue":"3","key":"2025102715480129000_CIT0010","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1389450116666150202161500","article-title":"Cardiovascular complications in inflammatory bowel disease","volume":"16","author":"Schicho","year":"2015","journal-title":"Curr Drug Targets."},{"issue":"6","key":"2025102715480129000_CIT0011","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"22","key":"2025102715480129000_CIT0012","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","article-title":"Comorbidity in inflammatory bowel disease","volume":"17","author":"Roman","year":"2011","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2025102715480129000_CIT0013","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025102715480129000_CIT0014","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"2025102715480129000_CIT0015","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000509544","article-title":"Malignancies in inflammatory bowel disease","volume":"101","author":"Greuter","year":"2020","journal-title":"Digestion."},{"issue":"9","key":"2025102715480129000_CIT0016","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist."},{"author":"US Food and Drug Administration","key":"2025102715480129000_CIT0017"},{"author":"US Food and Drug Administration","key":"2025102715480129000_CIT0018"},{"author":"EMA","key":"2025102715480129000_CIT0019"},{"issue":"10383","key":"2025102715480129000_CIT0020","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"2","key":"2025102715480129000_CIT0021","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2025102715480129000_CIT0022","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"2025102715480129000_CIT0023","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13\u2005222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025102715480129000_CIT0024","doi-asserted-by":"publisher","first-page":"e24729","DOI":"10.1097\/MD.0000000000024729","article-title":"Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients","volume":"100","author":"Juliao-Banos","year":"2021","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"2025102715480129000_CIT0025","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12876-022-02578-2","article-title":"Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study","volume":"22","author":"Mosli","year":"2022","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"2025102715480129000_CIT0026","doi-asserted-by":"publisher","first-page":"733","DOI":"10.18999\/nagjms.84.4.733","article-title":"Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases","volume":"84","author":"Rodriguez Meza","year":"2022","journal-title":"Nagoya J Med Sci."},{"issue":"3","key":"2025102715480129000_CIT0027","doi-asserted-by":"publisher","first-page":"otae040","DOI":"10.1093\/crocol\/otae040","article-title":"Treatment pathways in patients with Crohn\u2019s disease and ulcerative colitis: understanding the road to advanced therapy","volume":"6","author":"Siegel","year":"2024","journal-title":"Crohns Colitis 360."},{"issue":"1","key":"2025102715480129000_CIT0028","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjgast-2020-000573","article-title":"Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study","volume":"8","author":"Irving","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"6","key":"2025102715480129000_CIT0029","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025102715480129000_CIT0030","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-2004-823066","article-title":"Medical treatment of ulcerative colitis","volume":"17","author":"Mahadevan","year":"2004","journal-title":"Clin Colon Rectal Surg"},{"issue":"9","key":"2025102715480129000_CIT0031","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/MIB.0000000000000065","article-title":"Hepatobiliary manifestations of inflammatory bowel disease","volume":"20","author":"Yarur","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2025102715480129000_CIT0032","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025102715480129000_CIT0033","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756283X11405250","article-title":"Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease","volume":"4","author":"Williams","year":"2011","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"2025102715480129000_CIT0034","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40266-022-00943-0","article-title":"Ulcerative colitis in adulthood and in older patients: same disease, same outcome, same risks","volume":"39","author":"Fries","year":"2022","journal-title":"Drugs Aging."},{"key":"2025102715480129000_CIT0035","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"2025102715480129000_CIT0036","doi-asserted-by":"publisher","first-page":"141","DOI":"10.18553\/jmcp.2024.30.2.141","article-title":"Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States","volume":"30","author":"Zhdanava","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"Supplement_1","key":"2025102715480129000_CIT0037","doi-asserted-by":"publisher","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","article-title":"P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials","volume":"17","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"14","key":"2025102715480129000_CIT0038","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"Supplement_1","key":"2025102715480129000_CIT0039","doi-asserted-by":"publisher","first-page":"i534","DOI":"10.1093\/ecco-jcc\/jjac190.0535","article-title":"P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the true North open-label extension","volume":"17","author":"Panaccione","year":"2023","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf067\/62923889\/izaf067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2757\/62923889\/izaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2757\/62923889\/izaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:48:10Z","timestamp":1761594490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/10\/2757\/8113033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,12]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf067","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,4,12]]}}}